Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|January 17, 2001

Ross retires from Imatron

Terry Ross has stepped down as president of Imatron, although he will remain a member of the board, focusing on strategic business development. His vacated position will not be filled, nor will his office, which Imatron has already turned into a

Terry Ross has stepped down as president of Imatron, although he will remain a member of the board, focusing on strategic business development. His vacated position will not be filled, nor will his office, which Imatron has already turned into a library.

The position of president was created in 1998 as an enticement for Ross to lead the company. The agreement then was for Ross to stay just two years, long enough to redirect Imatron toward more profitable activities. He remained longer than initially planned. But for the last six weeks Ross has been on vacation. His retirement was not announced until Ross was satisfied that the company was functioning well without him.

CEO S. Lewis Meyer has taken over the helm.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.